Opinion

Video

Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

Author(s):

Jason Porter, MD

A key opinion leader examines the combination therapy of amivantamab and lazertinib in the CHRYSALIS-2 study for treatment-naïve patients or those with 2 or more prior lines of therapy, and its potential implications for non-small cell lung cancer treatment.

Video content above is prompted by the following questions:

  • Discuss the data that was presented at the ASCO 2024 on combination use amivantamab and lazertinib in the CHRYSALIS-2 study for patients who were treatment-naïve or had ≤ 2 prior lines.
  • Based on this study, how do you think amivantamab plus lazertinib compares with other current therapies used for EGFR mutations in NSCLC?
  • How might the safety data from this study impact treatment decisions and management strategies in clinical practice?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
5 experts in this video
5 experts in this video
Samir Shah, MD, MMM, FACR
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
1 expert in this video
5 experts in this video
Related Content
FDA Approved | Image Credit: wladimir1804-stock.adobe.com
June 11th 2025

Taletrectinib Approved for ROS1-Positive NSCLC

Maggie L. Shaw
This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for the same patient population, as well as additional non–small cell lung cancer (NSCLC) indications.
FDA Approved | Image credit: chrisdorney – stock.adobe.com
May 14th 2025

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

Hayden E. Klein
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
Krazati packaging | Image credit: Mirati Therapeutics
March 28th 2025

Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-Line Treatment of KRAS-Mutated NSCLC

Mary Caffrey
Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC). A phase 3 trial is enrolling now.
Ioana Bonta, MD
February 20th 2025

NSCLC Advancements Offer Hope, but Disparities Persist

Kyle Munz Ioana Bonta, MD
Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Ryan Nguyen, DO
January 1st 2025

AI in Oncology: Opportunities and Challenges for NSCLC

Skylar Jeremias
Ryan Nguyen, DO, University of Illinois Chicago, highlights the importance of personalized care for patients who have non–small cell lung cancer (NSCLC) and the potential of artificial intelligence (AI) in oncology, while cautioning against its limitations, including the risk of unsupported recommendations.
WCLC Highlights Thumbnail
December 27th 2024

ICYMI: Highlights From WCLC 2024

Maggie L. Shaw
The 2024 World Conference on Lung Cancer (WCLC) took place in San Diego, California, from September 7 to 10, 2024.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo